Losartan Potassium/HCTZ — $0 on Listed Strengths
Losartan Potassium/HCTZ is $0 on listed strengths only. Other strengths are not a blanket $0.
Losartan Potassium/HCTZ Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $173.00 |
$0 on listed strengths: 100/12.5mg Tablets (max 90); 100/25mg Tablets (max 90); 50/12.5mg Tablets (max 90)
About Losartan Potassium/HCTZ
Losartan Potassium/HCTZ is a prescription medication. Ask your doctor if Losartan Potassium/HCTZ is right for you.
How to Check Losartan Potassium/HCTZ Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Losartan Potassium/HCTZ at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
What Losartan Potassium/HCTZ is approved for (FDA label)
Losartan potassium and hydrochlorothiazide tablets are a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction.
Source: Read the full FDA label on DailyMed. Label effective date: August 7, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Boxed warning for Losartan Potassium/HCTZ (FDA label)
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium and hydrochlorothiazide tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue losartan potassium and hydrochlorothiazide tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
Source: FDA prescribing information (DailyMed). Set ID: 446e6998-01f6-4de0-be57-7fecf5448e95. SPL document ID: 58773077-d3b7-5c35-e063-6294a90a5aff. Label effective date: August 7, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Losartan Potassium/HCTZ (FDA label)
Losartan potassium and hydrochlorothiazide tablets USP, 100 mg/25 mg are yellow, capsule-shaped, film-coated tablets, debossed with “HH” on one side and “212” on the other side. Tablets (losartan potassium/hydrochlorothiazide content): 100 mg/25 mg. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 446e6998-01f6-4de0-be57-7fecf5448e95. SPL document ID: 58773077-d3b7-5c35-e063-6294a90a5aff. Label effective date: August 7, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Losartan Potassium/HCTZ (FDA label)
Most common adverse reactions (incidence ≥2% and greater than placebo) are dizziness, upper respiratory infection, cough, and back pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare US, LLC at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Losartan potassium-hydrochlorothiazide has been evaluated for safety in 858 patients treated for essential hypertension and 3,889 patients treated for hypertension and left ventricular hypertrophy.
Source: FDA prescribing information (DailyMed). Set ID: 446e6998-01f6-4de0-be57-7fecf5448e95. SPL document ID: 58773077-d3b7-5c35-e063-6294a90a5aff. Label effective date: August 7, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Losartan Potassium/HCTZ (FDA label)
Losartan potassium and hydrochlorothiazide tablets are contraindicated: In patients who are hypersensitive to any component of this product. In patients with anuria For coadministration with aliskiren in patients with diabetes Hypersensitivity to any component of losartan potassium and hydrochlorothiazide tablets. ( 4 ) Anuria. ( 4 ) Coadministration with aliskiren in patients with diabetes. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 446e6998-01f6-4de0-be57-7fecf5448e95. SPL document ID: 58773077-d3b7-5c35-e063-6294a90a5aff. Label effective date: August 7, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Losartan Potassium/HCTZ (FDA label)
Hypotension: Correct volume or salt depletion prior to administration of losartan potassium and hydrochlorothiazide tablets. ( 5.2 ) Monitor renal function and potassium in susceptible patients. ( 5.3 ) Observe for clinical signs of fluid or electrolyte imbalance. ( 5.5 ) Acute angle-closure glaucoma. ( 5.6 ) Exacerbation of systemic lupus erythematosus. ( 5.7 ) 5.1 Fetal Toxicity Losartan potassium and hydrochlorothiazide tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue losartan potassium and hydrochlorothiazide tablets as soon as possible.
Source: FDA prescribing information (DailyMed). Set ID: 446e6998-01f6-4de0-be57-7fecf5448e95. SPL document ID: 58773077-d3b7-5c35-e063-6294a90a5aff. Label effective date: August 7, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Losartan Potassium/HCTZ (FDA label)
Agents increasing serum potassium: Risk of hyperkalemia. ( 7.1 ) Lithium: Risk of lithium toxicity. ( 7.2 ) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7.3 ) Dual inhibition of the renin-angiotensin system: increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7.4 ) Antidiabetic drugs: dosage adjustment of antidiabetic may be required. ( 7.5 ) Cholestyramine and colestipol: Reduced absorption of thiazides. ( 7.5 ) 7.1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics.
Source: FDA prescribing information (DailyMed). Set ID: 446e6998-01f6-4de0-be57-7fecf5448e95. SPL document ID: 58773077-d3b7-5c35-e063-6294a90a5aff. Label effective date: August 7, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.